<table className="table"><caption><p>Preventive Migraine Therapies<sup>a</sup></p></caption><thead><tr><th colSpan="1" rowSpan="1"><p>Drug</p></th><th colSpan="1" rowSpan="1"><p>Migraine Type (Evidence Level<sup>b</sup>)</p></th></tr><tr><th colSpan="2" rowSpan="1"><p>Nonspecific Agents</p></th></tr></thead><tbody><tr className="group_1-1 row-odd"><td colSpan="1" rowSpan="1"><p>Propranolol</p></td><td colSpan="1" rowSpan="1"><p>Episodic (A)</p></td></tr><tr className="group_1-2 row-even"><td colSpan="1" rowSpan="1"><p>Metoprolol</p></td><td colSpan="1" rowSpan="1"><p>Episodic (A)</p></td></tr><tr className="group_1-3 row-odd"><td colSpan="1" rowSpan="1"><p>Atenolol</p></td><td colSpan="1" rowSpan="1"><p>Episodic (B)</p></td></tr><tr className="group_1-4 row-even"><td colSpan="1" rowSpan="1"><p>Timolol</p></td><td colSpan="1" rowSpan="1"><p>Episodic (A)</p></td></tr><tr className="group_1-5 row-odd"><td colSpan="1" rowSpan="1"><p>Valproate</p></td><td colSpan="1" rowSpan="1"><p>Episodic (A)</p></td></tr><tr className="group_1-6 row-even"><td colSpan="1" rowSpan="1"><p>Topiramate</p></td><td colSpan="1" rowSpan="1"><p>Episodic and chronic (A)</p></td></tr><tr className="group_1-7 row-odd"><td colSpan="1" rowSpan="1"><p>Candesartan</p></td><td colSpan="1" rowSpan="1"><p>Episodic (A)</p></td></tr><tr className="group_1-8 row-even"><td colSpan="1" rowSpan="1"><p>Amitriptyline</p></td><td colSpan="1" rowSpan="1"><p>Episodic (B)</p></td></tr><tr className="group_1-9 row-odd"><td colSpan="1" rowSpan="1"><p>Venlafaxine</p></td><td colSpan="1" rowSpan="1"><p>Episodic (B)</p></td></tr><tr className="group_1-10 row-even"><td colSpan="1" rowSpan="1"><p>Onabotulinum toxin A</p></td><td colSpan="1" rowSpan="1"><p>Chronic (A)</p></td></tr><tr><th colSpan="2" rowSpan="1"><p>Migraine-Specific Parenteral Agents</p></th></tr><tr className="group_2-1 row-odd"><td colSpan="1" rowSpan="1"><p>Eptinezumab</p></td><td colSpan="1" rowSpan="1"><p>Episodic and chronic (A)</p></td></tr><tr className="group_2-2 row-even"><td colSpan="1" rowSpan="1"><p>Erenumab</p></td><td colSpan="1" rowSpan="1"><p>Episodic and chronic (A)</p></td></tr><tr className="group_2-3 row-odd"><td colSpan="1" rowSpan="1"><p>Fremanezumab</p></td><td colSpan="1" rowSpan="1"><p>Episodic and chronic (A)</p></td></tr><tr className="group_2-4 row-even"><td colSpan="1" rowSpan="1"><p>Galcanezumab</p></td><td colSpan="1" rowSpan="1"><p>Episodic and chronic (A)</p></td></tr><tr><th colSpan="2" rowSpan="1"><p>Migraine-Specific Oral Agents</p></th></tr><tr className="group_3-1 row-odd"><td colSpan="1" rowSpan="1"><p>Atogepant</p></td><td colSpan="1" rowSpan="1"><p>Episodic and chronic (A)</p></td></tr><tr className="group_3-2 row-even"><td colSpan="1" rowSpan="1"><p>Rimegepant</p></td><td colSpan="1" rowSpan="1"><p>Episodic (A)</p></td></tr></tbody></table>